share_log

Cosmos Health Enters Into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X

Cosmos Health Enters Into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X

Cosmos Health 簽訂收購 2 型糖尿病治療藥物 DIABIT-IS X 的最終協議
Accesswire ·  2023/12/20 22:15

CHICAGO, IL / ACCESSWIRE / December 20, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a definitive agreement, subject to customary closing conditions, with a related party to acquire the license and rights for "DIABIT-IS X", a drug used in the treatment of type-2 diabetes.

伊利諾伊州芝加哥/ACCESSWIRE/2023年12月20日/Cosmos Health Inc.(“Cosmos Health” 或 “公司”)(納斯達克股票代碼:COSM)是一家從事創新研發的多元化、垂直整合的全球醫療保健集團、專有藥品和營養品品牌的所有者、醫療保健產品的製造商和分銷商以及遠程醫療平台的運營商,今天宣佈,它已簽訂最終協議,但須遵守慣例成交條件,與關聯方一起獲得 “DIABIT-IS X”(一種用於治療以下疾病的藥物)的許可和權利2 型糖尿病。

DIABIT-IS X is one the first generics to be launched in Europe following the European patent expiration in June 2024 of the branded "Januvia" owned by Merck. Januvia, along with its sister drug Janumet, generated combined global sales of $4.5 billion in 2022, and is approaching the expiration of its primary patent, held by Merck. In this context, Cosmos Health, as one of the first movers through the acquisition of DIABIT-IS X, is well-positioned to capture a significant share of the European market.

繼默沙東旗下的 “Januvia” 品牌的歐洲專利於2024年6月到期後,DIABIT-IS X是首批在歐洲推出的仿製藥之一。Januvia及其姊妹藥Janumet在2022年創造了45億美元的全球總銷售額,默沙東持有的主要專利即將到期。在這種情況下,作爲收購DIABIT-IS X的先行者之一,Cosmos Health完全有能力佔領歐洲市場的巨大份額。

DIABIT-IS X is a medicine that contains the active substance sitagliptin. It will be available in tablets to be used in patients with type-2 diabetes to improve the control of blood glucose (sugar) levels. Type-2 diabetes occurs when the pancreas doesn't produce enough insulin or the body doesn't use insulin properly. DIABIT-IS X, containing sitagliptin, inhibits the breakdown of incretin hormones which stimulate insulin production after meals. Sitagliptin boosts insulin when blood glucose is high and doesn't activate at normal blood sugar levels. It also helps reduce liver glucose production, assisting in blood glucose regulation for type-2 diabetes management.

DIABIT-IS X 是一種含有活性物質西他列汀的藥物。它將以片劑形式提供,用於2型糖尿病患者,以改善血糖(糖)水平的控制。當胰腺不能產生足夠的胰島素或人體不能正確使用胰島素時,就會發生2型糖尿病。含有西格列汀的 DIABIT-IS X 可抑制腸促胰島素激素的分解,促胰島素激素在飯後刺激胰島素的產生。當血糖升高時,西他列汀會增強胰島素,並且在正常血糖水平下無法激活。它還有助於減少肝臟葡萄糖的產生,幫助調節血糖,管理2型糖尿病。

Greg Siokas, Chief Executive Officer of Cosmos Health, stated: "We are expanding into new markets to enhance and diversify our revenue streams. We are pleased to announce a definitive agreement to acquire DIABIT-IS X, which positions Cosmos as one of the first companies to launch a generic Type-2 diabetes medicine in Europe. Considering the multi-billion-dollar market size, we anticipate generating substantial profits from this investment."

Cosmos Health首席執行官格雷格·西奧卡斯表示:“我們正在向新市場擴張,以增強和多元化我們的收入來源。我們很高興地宣佈收購DIABIT-IS X的最終協議,這使Cosmos成爲首批在歐洲推出仿製2型糖尿病藥物的公司之一。考慮到數十億美元的市場規模,我們預計這項投資將帶來可觀的利潤。”

About Cosmos Health Inc.

關於 Cosmos Health Inc

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Chicago, Illinois, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency, it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at , , , and , as well as LinkedIn and X.

Cosmos Health Inc.(納斯達克股票代碼:COSM)於2009年在伊利諾伊州芝加哥成立,是一家多元化、垂直整合的全球醫療保健集團。該公司擁有一系列專有藥品和營養品品牌,包括Sky Premium Life、Mediterranation、bio-bebe和C-Sept。它通過其子公司Cana Laboratories S.A.(根據歐洲良好生產規範(GMP)獲得許可並獲得歐洲藥品管理局的認證,在歐盟境內生產藥品、食品補充劑、化妝品、殺菌劑和醫療器械。Cosmos Health還通過其在希臘和英國的子公司向零售藥房和批發分銷商分銷各種藥品和輔助藥物,包括品牌仿製藥和非處方藥。此外,該公司還建立了針對肥胖、糖尿病和癌症等主要健康疾病的研發合作伙伴關係,並專注於新型專利營養品、特種根提取物、專有複合仿製藥和創新的非處方藥產品的研發。Cosmos Health還通過收購總部位於美國德克薩斯州的ZipDoctor, Inc. 進入了遠程醫療領域。憑藉全球分銷平台,公司目前正在歐洲、亞洲和北美擴張,並在希臘塞薩洛尼基和雅典以及英國哈洛設有辦事處和配送中心。更多信息可在、、和、以及 LinkedIn 和 X 上找到。

Forward-Looking Statements

前瞻性陳述

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

除本新聞稿中包含的歷史信息外,此處描述的事項可能包含經修訂的1933年《證券法》第27A條和經修訂的1934年《證券交易法》第21E條所指的前瞻性陳述。前面有、後面跟着或以其他方式的陳述包括 “相信”、“期望”、“預期”、“打算”、“項目”、“估計”、“計劃” 和類似的表達方式或未來或條件動詞,如 “將”、“會”、“可能” 和 “可能”,通常是前瞻性的,而不是歷史事實,儘管並非所有前瞻性陳述都包含前述內容。這些陳述涉及未知的風險和不確定性,可能對本文討論的事項產生單獨或重大影響,其原因是公司無法控制的各種原因,包括但不限於公司籌集足夠資金以實施其業務計劃的能力、COVID-19 疫情和烏克蘭戰爭對公司業務、運營和總體經濟的影響,以及公司成功開發和商業化其專有產品的能力和技術。提醒讀者不要過分依賴這些前瞻性陳述,因爲實際結果可能與此處包含的前瞻性陳述中描述的結果存在重大差異。敦促讀者閱讀公司向美國證券交易委員會提交的文件中列出的風險因素,這些文件可在美國證券交易委員會的網站(www.sec.gov)上查閱。無論是由於新信息、未來事件還是其他原因,公司均不打算或沒有義務更新或修改任何前瞻性陳述。

Investor Relations

投資者關係

Paul Lampoutis
Capital Link, Inc.
230 Park Avenue, Suite 1540
New York, N.Y. 10169
Tel.: (212) 661-7566
Fax: (212) 661-7526
E-Mail: Cosmoshealth@capitallink.com

保羅·蘭普蒂斯
Capital Link, Inc
公園大道 230 號,1540 套房
紐約州紐約 10169
電話:(212) 661-7566
傳真:(212) 661-7526
電子郵件:Cosmoshealth@capitallink.com

SOURCE: Cosmos Health Inc.

來源:Cosmos Health Inc.


View the original press release on accesswire.com
在 accesswire.com 上查看原始新聞稿

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論